Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kontafarma China Holdings Ltd ( (HK:1312) ) just unveiled an announcement.
Kontafarma China Holdings reported audited revenue of HK$914.7 million for 2025, slightly up from HK$897.5 million a year earlier, but gross profit remained broadly flat at HK$513.6 million. The group’s cost of sales, distribution, and administrative expenses continued to weigh on margins, limiting any operational uplift from the modest top-line growth.
The company swung to a significantly deeper net loss of HK$482.6 million in 2025, compared with a loss of HK$99.0 million in 2024, driven mainly by sharp increases in other losses and expected credit loss impairments. The heavier loss, which translated into a wider basic loss per share of 7.67 HK cents, underlines mounting pressure on asset quality and profitability, signaling heightened risks for shareholders and minority investors despite stable revenues.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates as a diversified group in China. The company generates revenue from the sale of goods and services across its business segments, with operations exposed to foreign exchange movements due to its international footprint.
Average Trading Volume: 1,337,529
Technical Sentiment Signal: Sell
Current Market Cap: HK$161.8M
See more data about 1312 stock on TipRanks’ Stock Analysis page.